The earnings call highlighted a significant partnership with Dynavax, which boosts financial stability and validates Vaxart's technology. Positive developments in the norovirus program and increased revenue are notable. However, the stop work order from BARDA and delays in norovirus trials present challenges.
Company Guidance
During the Vaxart Third Quarter 2025 Financial Results Conference Call, significant guidance was provided regarding the company's strategic direction and financial outlook. Vaxart announced a substantial partnership with Dynavax, potentially worth up to $700 million in license, regulatory, and milestone fees, along with royalties for their oral COVID-19 vaccine candidate. As part of the agreement, Dynavax will make an upfront payment of $25 million and a $5 million equity investment. This collaboration extends Vaxart's cash runway into the second quarter of 2027. Vaxart retains responsibility for the ongoing Phase IIb trial and, if Dynavax assumes further development, Vaxart could receive up to $195 million in regulatory milestone payments, $425 million in sales milestone payments, and tiered royalties. The company remains on track to report key data readouts in 2026, and the partnership with Dynavax is anticipated to bolster Vaxart's position in advancing other vaccine candidates, including norovirus, flu, and HPV, underscoring the transformative potential of their oral vaccine platform.
Strategic Partnership with Dynavax
Vaxart announced a partnership with Dynavax for their oral COVID-19 vaccine program, potentially worth up to $700 million, including an upfront license fee of $25 million and a $5 million equity investment. This extends Vaxart's cash runway to Q2 2027.
Positive Norovirus Vaccine Developments
Vaxart reported positive Phase I results for their second-generation norovirus vaccine, showing significant increases in antibody responses, with a potential for improved protection over the first-generation constructs.
Increased Revenue
Revenue for Q3 2025 was $72.4 million, a significant increase from $4.9 million in Q3 2024, primarily due to the BARDA contract.
Vaxart (VXRT) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VXRT Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2025
$0.36
$0.40
+11.11%
Aug 13, 2025
$0.37
$0.36
-2.70%
May 13, 2025
$0.42
$0.40
-4.76%
Mar 20, 2025
$0.57
$0.52
-8.77%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vaxart (VXRT) report earnings?
Vaxart (VXRT) is schdueled to report earning on Mar 19, 2026, TBA (Confirmed).
What is Vaxart (VXRT) earnings time?
Vaxart (VXRT) earnings time is at Mar 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.